Cancer

In vitro and mouse studies suggest class IIa-selective HDAC inhibitors could help treat cancer. In a mouse model of breast cancer, the class IIa HDAC inhibitor TMP195 increased macrophage infiltration in tumors and decreased tumor growth and the number of lung metastases compared with vehicle. Also in the model, TMP195 plus paclitaxel, carboplatin or an anti-PD-1 mAb decreased tumor burden compared with any agent alone. Next steps include optimizing the selectivity of TMP195 (see "Eating Cancer." BioCentury Innovations (April 13, 2017))...